Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

Background: OXi4503 is a tubulin-binding vascular disrupting agent that has recently completed a Cancer Research UK-sponsored phase I trial. Preclinical studies demonstrated early drug-induced apoptosis in tumour endothelial cells at 1-3 h and secondary tumour cell necrosis between 6 and 72 h. Metho...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Cummings, J, Zweifel, M, Smith, N, Ross, P, Peters, J, Rustin, G, Price, P, Middleton, MR, Ward, T, Dive, C
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	2012

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. nork Cummings, J, Zweifel, M, Smith, N, Ross, P, Peters, J, Rustin, G, Price, P, Middleton, MR, Ward, T, Dive, C

Argitaratua 2012

Journal article

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. nork Cummings, J, Zweifel, M, Smith, N, Ross, P, Peters, J, Rustin, G, Price, P, Middleton, MR, Ward, T, Dive, C

Antzeko izenburuak